Streetbeat News

Stock Prices

VGAS

Verde Clean Fuels (NASDAQ:VGAS) reported a Q2 EPS of $(0.14), a 16.67% decrease from $(0.12) YoY. The company ended the quarter with $23.2 million in cash and cash equivalents.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:43 am

HD

NVDA

PSFE

QQQ

SE

SPY

TME

VSAT

Wall Street is optimistic about benign inflation data, which could lead to a rate cut. Home Depot's weak guidance is weighing on the retail sector. Futures for Nasdaq and S&P 500 are slightly up, while Dow and Russell 2000 are down. Key stocks like Home Depot, Tencent Music, Sea Limited, Paysafe, and Viasat are experiencing significant premarket movements.

Portfolio Pulse from Shanthi Rexaline

August 13, 2024 | 11:41 am

CYBN

Cybin has completed an FDA Type B initial breakthrough therapy meeting and plans to initiate a Phase 3 program for CYB003 in treating major depressive disorder by late summer.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:40 am

HD

Home Depot (NYSE:HD) reported Q2 2024 earnings with a slight revenue miss and a decline in customer transactions. Despite weaker home improvement spending, the company raised its annual revenue outlook. HD shares are trading lower by 2.36% in the premarket.

Portfolio Pulse from Akanksha Bakshi

August 13, 2024 | 11:39 am

LUNR

Intuitive Machines has updated its 2024 revenue outlook to $210M-$240M, slightly higher than the previous lower bound of $200M. The company expects a 2.6x-3x increase in sales compared to the prior year. The Q2 cash balance is expected to be sufficient to fund operations for the next 12 months. The company is also expanding its backlog with key upcoming awards and plans to ship its mission two completed lander by Q4 2024.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:38 am

CYBN

Cybin is set to commence its Phase 3 pivotal program for CYB003 in late summer, following a Type B Initial Breakthrough Therapy meeting with the FDA. The company has selected 30 clinical sites across the US and Europe. In Phase 2, CYB003 showed a 75% remission rate from depression four months after two 16mg doses. Cybin expects to report 12-month efficacy data from Phase 2 in Q4 this year.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:37 am

XOMA

XOMA Corporation reported its Q2 2024 financial results, with GAAP EPS of $0.84, significantly beating the estimated loss of $(0.27). Additionally, sales reached $11.086 million, surpassing the $8.377 million estimate.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:36 am

MSGS

Madison Square Garden (MSGS) reported Q4 2024 GAAP EPS of $1.06, significantly beating the estimate of $0.45.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:33 am

PSTV

Plus Therapeutics announced that its CNSide Leptomeningeal Metastases FORSEE Trial met key primary and secondary endpoints. The trial demonstrated that CNSide influenced treatment decisions in over 90% of cases, surpassing the 20% primary endpoint target. The data were presented at the 2024 Society for NeuroOncology (SNO)/American Society for Clinical Oncology (ASCO) CNS Metastases Conference.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:32 am

VRPX

Virpax Pharmaceuticals reported a Q2 2024 GAAP EPS of $(1.75), which is significantly lower than the $(0.61) estimate. This discrepancy may impact investor sentiment negatively.

Portfolio Pulse from Benzinga Newsdesk

August 13, 2024 | 11:32 am